Business Context and Reporting Period
Company: Agenus Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 3, 2026
Event: Entry into a Material Definitive Agreement and Material Modification to Rights of Security Holders.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific contractual amendment.
Material Changes
On January 3, 2026, Agenus Inc., Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC entered into an Amendment and Release Agreement with Ligand Pharmaceuticals Incorporated ("Ligand"). Key terms include:
- Release of Liens: Ligand has released liens on certain of the Company's assets.
- Warrant Modification: In exchange for the lien release, the exercise price of a previously disclosed warrant was modified from $17.30 per share to $7.50 per share.
- Reference: This amendment relates to a Purchase and Sale Agreement and Warrant originally disclosed in an 8-K filed on May 7, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the implications of the warrant modification. The full text of the Amendment Agreement, with confidential terms redacted, is scheduled to be filed as an exhibit to the Company's next Annual Report on Form 10-K.
Investor Verification Checklist
- Verify the impact of the reduced warrant exercise price ($7.50) on potential future dilution.
- Confirm the specific assets from which Ligand's liens were released.
- Review the upcoming Form 10-K for the full text of the Amendment Agreement to understand any redacted confidential terms.
- Assess the remaining obligations under the original May 2024 Purchase and Sale Agreement.